Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 21.05.2026 FEX.LN IE00B8X9NW27 1,083,256.00 USD 118,613,954.98 109.498  ...
-

XiFin Applauds House Ways and Means Committee Advancement of the Main Street Pharmacy Access Act

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in AI-driven revenue cycle management solutions and a business partner to more than half of pharmacies across the United States, today expressed strong support for H.R. 3164, the Main Street Pharmacy Access Act, which was advanced by the full House Ways and Means Committee after mark-up. The legislation has earned broad, bipartisan support, with more than 100 Congressional co-sponsors and the support of major healthcare organizations. XiFin join...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100® Moderate Buffer UCITS ETF - March 21.05.2026 QMAR.LN IE0006S0EBF2 50,002.00 USD 1,238,282.43 24.765  ...
-

Slate Grocery REIT Special Committee to Review Strategic Alternatives

TORONTO--(BUSINESS WIRE)--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), today confirmed that the Board of Trustees has established a special committee of independent trustees (the “Special Committee”) in response to an unsolicited proposal (the “Proposal”) received from affiliates of Slate Asset Management, the external manager of the REIT (the “Manager”). The Special Committee has a broad mandate to consider and evaluate a broad range of strategic alternatives, including, but not...
-

Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary c...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 21.05.2026 FTAI IE000YIQZ0H6 200,002.00 USD 5,838,012.81 29.190  ...
-

AI & Tech Sandbox Unveils Cannes Lions 2026 Programming Focused on Learning, Discovery, and What’s Next in AI

DALLAS & NEW YORK & LONDON--(BUSINESS WIRE)--The AI & Tech Sandbox, powered by PMG, today announced the first wave of programming for its Cannes Lions 2026 experience on Miramar Beach....
-

Nakamoto Announces Expansion of Board of Directors

NASHVILLE, Tenn.--(BUSINESS WIRE)--Nakamoto Inc. (Nasdaq: NAKA) (“Nakamoto” or the “Company”) today announced that its Board of Directors (the “Board”) has increased the size of the Board from six to seven members and appointed Tyler Evans, Chief Investment Officer of Nakamoto, to fill the newly created vacancy as a Class II Director. The appointment is effective May 22, 2026. With his appointment to the Board, Mr. Evans expands his leadership role at Nakamoto alongside his position as Chief In...
-

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

TOKYO--(BUSINESS WIRE)--Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors...
-

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i...